oligodeoxyribonucleotides

Summary

Summary: A group of deoxyribonucleotides (up to 12) in which the phosphate residues of each deoxyribonucleotide act as bridges in forming diester linkages between the deoxyribose moieties.

Top Publications

  1. ncbi Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides
    Veit Hornung
    Department of Internal Medicine, Division of Clinical Pharmacology, University of Munich, Munich, Germany
    J Immunol 168:4531-7. 2002
  2. pmc CpG DNA as a vaccine adjuvant
    Christian Bode
    Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA
    Expert Rev Vaccines 10:499-511. 2011
  3. pmc Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
    Paula J Bates
    James Graham Brown Cancer Center, Department of Medicine, University of Louisville, Louisville, Kentucky 40202, USA
    Exp Mol Pathol 86:151-64. 2009
  4. pmc Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding
    Robert F Ashman
    Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
    Int Immunol 23:203-14. 2011
  5. ncbi Therapeutic potential of Toll-like receptor 9 activation
    Arthur M Krieg
    Coley Pharmaceutical Group, Inc, 93 Worcester Street, Suite 101, Wellesley, Massachusetts 02481, USA
    Nat Rev Drug Discov 5:471-84. 2006
  6. pmc Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement
    Marcello Chieppa
    Lymphocyte Biology Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Bethesda, MD 20892, USA
    J Exp Med 203:2841-52. 2006
  7. ncbi Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE
    Jane Tian
    Inflammation and Autoimmune Group, Research Department, MedImmune, Gaithersburg, Maryland 20878, USA
    Nat Immunol 8:487-96. 2007
  8. ncbi Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy
    Kaley D Wilson
    Centre for Drug Research and Development, University of British Columbia, Vancouver, Canada
    Adv Drug Deliv Rev 61:233-42. 2009
  9. pmc A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism
    E Merit Reyes-Reyes
    Departments of Medicine and Biochemistry and Molecular Biology, James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky 40202, USA
    Cancer Res 70:8617-29. 2010
  10. pmc Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3
    Miwa Sasai
    Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA
    Science 329:1530-4. 2010

Research Grants

  1. Targeted Lipopolyplexes for Oligonucleotide Delivery to AML
    Robert J Lee; Fiscal Year: 2012
  2. Chemistry and Biology of DNA Carboxyalkylation
    Yinsheng Wang; Fiscal Year: 2013
  3. Cellular and Molecular Effectors of Synovitis
    Paul J Anderson; Fiscal Year: 2010
  4. ROS-induced Nucleic Acid Damage
    Yinsheng Wang; Fiscal Year: 2010
  5. SOMATOSTATIN RECEPTORS--CLASSIFICATION OF NEUROBLASTOMAS
    M O DORISIO; Fiscal Year: 1999
  6. (2'-5')AN DEPENDENT ENDONUCLEASE AND INTERFERON ACTION
    GEORGIA SMITH; Fiscal Year: 1992
  7. Exercise, Antioxidants, and I-R Injury
    Scott Powers; Fiscal Year: 2006
  8. ONTOGENY AND EXPRESSION OF THE CFTR IN BRAIN
    ANDREW MULBERG; Fiscal Year: 2003
  9. REGULATION OF 06-METHYLGUANINE DNA METHYLTRANSFERASE
    Edward Bresnick; Fiscal Year: 1991
  10. DNA SYNTHESIS AND HYDROLYSIS
    RICHARD BRODY; Fiscal Year: 1990

Detail Information

Publications311 found, 100 shown here

  1. ncbi Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides
    Veit Hornung
    Department of Internal Medicine, Division of Clinical Pharmacology, University of Munich, Munich, Germany
    J Immunol 168:4531-7. 2002
    ..In addition, selective regulation of TLR7 expression in PDC and B cells by CpG ODN revealed TLR7 as a candidate TLR potentially involved in modulating the recognition of CpG motifs...
  2. pmc CpG DNA as a vaccine adjuvant
    Christian Bode
    Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA
    Expert Rev Vaccines 10:499-511. 2011
    ..Clinical trials demonstrate that CpG ODNs have a good safety profile and increase the immunogenicity of coadministered vaccines...
  3. pmc Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
    Paula J Bates
    James Graham Brown Cancer Center, Department of Medicine, University of Louisville, Louisville, Kentucky 40202, USA
    Exp Mol Pathol 86:151-64. 2009
    ..Thus, the serendipitous discovery of the G-rich oligonucleotides also led to the identification of nucleolin as a new molecular target for cancer therapy...
  4. pmc Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding
    Robert F Ashman
    Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
    Int Immunol 23:203-14. 2011
    ..Inhibitory oligodeoxyribonucleotides (INH-ODN) have been developed that selectively block activation of mouse TLR9...
  5. ncbi Therapeutic potential of Toll-like receptor 9 activation
    Arthur M Krieg
    Coley Pharmaceutical Group, Inc, 93 Worcester Street, Suite 101, Wellesley, Massachusetts 02481, USA
    Nat Rev Drug Discov 5:471-84. 2006
    ....
  6. pmc Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement
    Marcello Chieppa
    Lymphocyte Biology Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Bethesda, MD 20892, USA
    J Exp Med 203:2841-52. 2006
    ..Collectively, these findings support a model in which epithelial cell TLR signaling upon exposure to microbial stimuli induces active DC sampling of the gut lumen at sites distant from organized lymphoid tissues...
  7. ncbi Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE
    Jane Tian
    Inflammation and Autoimmune Group, Research Department, MedImmune, Gaithersburg, Maryland 20878, USA
    Nat Immunol 8:487-96. 2007
    ..Our data demonstrate a mechanism by which HMGB1 and RAGE activate plasmacytoid dendritic cells and B cells in response to DNA and contribute to autoimmune pathogenesis...
  8. ncbi Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy
    Kaley D Wilson
    Centre for Drug Research and Development, University of British Columbia, Vancouver, Canada
    Adv Drug Deliv Rev 61:233-42. 2009
    ..Lipid-encapsulation provides a feasible strategy to optimize the immunostimulatory activity and immunotherapeutic efficacy of CpG ODN, thereby allowing their full clinical potential to be realized...
  9. pmc A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism
    E Merit Reyes-Reyes
    Departments of Medicine and Biochemistry and Molecular Biology, James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky 40202, USA
    Cancer Res 70:8617-29. 2010
    ..The data suggest a new model for AS1411 action as well as a new role for nucleolin in stimulating macropinocytosis, a process with potential applications in drug delivery...
  10. pmc Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3
    Miwa Sasai
    Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA
    Science 329:1530-4. 2010
    ..Our results reveal an intracellular mechanism for bifurcation of TLR9 signals by selective receptor trafficking within the endosomal system...
  11. pmc A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics
    J SantaLucia
    Department of Chemistry, Wayne State University, Detroit, MI 48202, USA
    Proc Natl Acad Sci U S A 95:1460-5. 1998
    ..Further, a single set of parameters, derived from 108 oligonucleotide duplexes, adequately describes polymer and oligomer thermodynamics. Empirical salt dependencies are also derived for oligonucleotides and polymers...
  12. pmc PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation
    Cristiana Guiducci
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    J Exp Med 205:315-22. 2008
    ..Thus, PI3K selectively controls type I IFN production by regulating IRF-7 nuclear translocation in human pDCs and could serve as a novel target to inhibit pathogenic type I IFN in autoimmune diseases...
  13. ncbi The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells
    Sridharan Soundararajan
    Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA
    Cancer Res 68:2358-65. 2008
    ..This interferes with the stabilization of bcl-2 mRNA by nucleolin and may be one mechanism by which AS1411 induces tumor cell death...
  14. ncbi Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection
    Jaap T van Dissel
    Leiden University Medical Center LUMC, Department of Infectious Diseases, Leiden, The Netherlands j t van
    Vaccine 29:2100-9. 2011
    ..The strong responses persisted through 32 weeks of follow-up, indicating the induction of a persistent memory response in the vaccine recipients...
  15. ncbi CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
    H L Davis
    Loeb Research Institute, Ottawa Civic Hospital, ON, Canada
    J Immunol 160:870-6. 1998
    ..These studies demonstrate that CpG ODN are promising new immune enhancers for vaccination applications...
  16. ncbi Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments
    Parviz Ahmad-Nejad
    Institute of Medical Microbiology, Immunology and Hygiene, Technische Universitat Munchen, Munich, Germany
    Eur J Immunol 32:1958-68. 2002
    ..These data stress the need to characterize individual TLR at the very beginning of signal initiation in order to understand their diverse biological functions...
  17. pmc Acquisition of adult-like TLR4 and TLR9 responses during the first year of life
    Muriel Nguyen
    Institute for Medical Immunology, Universite Libre de Bruxelles, Gosselies, Belgium
    PLoS ONE 5:e10407. 2010
    ..Herein, we analyzed the evolution of these responses within the first year of life...
  18. ncbi Priming with synthetic oligonucleotides attenuates pressure overload-induced inflammation and cardiac hypertrophy in mice
    Markus Velten
    Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Sigmund Freud Strasse 25, Bonn D 53105, Germany
    Cardiovasc Res 96:422-32. 2012
    ..In the present study, we investigated whether pre-treatment with the synthetic TLR9 ligands 1668-thioate or 1612-thioate modulates the progression of TAC-induced cardiac inflammation and hypertrophy...
  19. pmc CpG-ODN, the TLR9 agonist, attenuates myocardial ischemia/reperfusion injury: involving activation of PI3K/Akt signaling
    Zhijuan Cao
    Department of Surgery, East Tennessee State University, Johnson City, TN 37614, USA
    Biochim Biophys Acta 1832:96-104. 2013
    ..Toll-like receptors (TLRs) have been implicated in myocardial ischemia/reperfusion (I/R) injury. The TLR9 ligand, CpG-ODN has been reported to improve cell survival. We examined effect of CpG-ODN on myocardial I/R injury...
  20. ncbi Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation
    Ihsan Gursel
    Section of Retroviral Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Immunol 171:1393-400. 2003
    ..These findings are the first to establish that specific host-derived molecules can down-regulate the innate immune response elicited by a TLR ligand...
  21. ncbi Discovery and development of anticancer aptamers
    Christopher R Ireson
    Antisoma Research Laboratories, London, UK
    Mol Cancer Ther 5:2957-62. 2006
    ..In preclinical studies, additional aptamers have been described against several cancer targets, such as tenascin-C, the transcription factor signal transducer and activator of transcription 3, and antiapoptotic and Ku proteins...
  22. ncbi Maintenance of serological memory by polyclonal activation of human memory B cells
    Nadia L Bernasconi
    Institute for Research in Biomedicine, Via Vela 6, CH 6500 Bellinzona, Switzerland
    Science 298:2199-202. 2002
    ..Although antigen boosting leads to a transient increase in specific antibody levels, ongoing polyclonal activation of memory B cells offers a means to maintain serological memory for a human lifetime...
  23. ncbi Use of CpG oligonucleotides in treatment of asthma and allergic disease
    David E Fonseca
    Roy J and Lucille A Carver College of Medicine, University of Iowa, USA
    Adv Drug Deliv Rev 61:256-62. 2009
    ..Further study of CpG-ODNs for the treatment of asthma and other atopic disorders is warranted by existing data...
  24. ncbi Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity
    Carole Bourquin
    Division of Clinical Pharmacology, Department of Internal Medicine, Ludwig Maximilian University of Munich, Munich, Germany
    J Immunol 181:2990-8. 2008
    ..We describe a novel strategy to target immunostimulatory oligonucleotides to the initiation site of the immune response while at the same time protecting from an indiscriminate and generalized activation of the immune system...
  25. ncbi Suppressive oligodeoxynucleotides inhibit atherosclerosis in ApoE(-/-) mice through modulation of Th1/Th2 balance
    Xiang Cheng
    Laboratory of Cardiovascular Immunology, Institute of Cardiology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China
    J Mol Cell Cardiol 45:168-75. 2008
    ..This study provides the first experimental evidence that suppressive ODNs inhibit the development of atherosclerosis through inhibition of the STAT1/4 and T-bet pathways, which further modulate the Th1/Th2 balance in vivo...
  26. pmc Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists
    Wenjun Meng
    Graduate School of Life Science, Hokkaido University, N10W8, Kita ku, Sapporo 060 0810, Japan
    BMC Biotechnol 11:88. 2011
    ..However, ODNs with a PTO backbone have been shown to have undesirable side effects. Thus, our goal was to develop nuclease-resistant, PD ODNs that are effective as human TLR9 (hTLR9) agonists...
  27. pmc CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion
    Miguel A Sanjuan
    Johnson and Johnson Pharmaceutical Research and Development, L L C, San Diego, CA 92121, USA
    J Cell Biol 172:1057-68. 2006
    ..The Src family pathway intersects the TLR9-MyD88 pathway by promoting the tyrosine phosphorylation of TLR9 and the recruitment of Syk to this receptor...
  28. pmc Formulation of vaccines containing CpG oligonucleotides and alum
    Joan A Aebig
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Rockville, MD, 20852 USA
    J Immunol Methods 323:139-46. 2007
    ..It also suggests that IP-10 assays are not a good basis for potency assays for alum-based vaccines containing CPG 7909...
  29. ncbi Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock
    Hidekazu Shirota
    Section of Retroviral Immunology, Center for Biologics Evaluation and Research, U S Food and Drug Administration, Bethesda, MD 20892, USA
    J Immunol 174:4579-83. 2005
    ..These findings suggest that suppressive ODN might be of use in the treatment of endotoxic shock...
  30. pmc Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates
    Ulrike Wille-Reece
    Cellular Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 203:1249-58. 2006
    ..These data provide insights for designing prime-boost immunization regimens to optimize Th1 and CD8+ T cell responses...
  31. pmc Intercalating nucleic acids containing insertions of 1-O-(1-pyrenylmethyl)glycerol: stabilisation of dsDNA and discrimination of DNA over RNA
    Ulf B Christensen
    Nucleic Acid Center, Department of Chemistry, University of Southern Denmark, DK 5230 Odense M, Denmark
    Nucleic Acids Res 30:4918-25. 2002
    ..pseudo-nucleotide (IPN), was synthesised and by standard methods inserted into 7mer and 13mer oligodeoxyribonucleotides (ODNs) to generate intercalating nucleic acids (INAs)...
  32. pmc Type I interferon dependence of plasmacytoid dendritic cell activation and migration
    Carine Asselin-Paturel
    Laboratory for Immunological Research, Schering Plough Research Institute, Dardilly 69571, France
    J Exp Med 201:1157-67. 2005
    ..These data demonstrate that mouse pDCs differ from cDCs in the in vivo response to TLR ligands, in terms of pattern and type I IFN requirement for activation and migration...
  33. pmc Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens
    N Kadowaki
    DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, CA 94304, USA
    J Exp Med 194:863-9. 2001
    ....
  34. ncbi CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases
    Dennis M Klinman
    Laboratory of Experimental Immunology, National Cancer Institute at Frederick, Frederick, MD 21702, United States
    Adv Drug Deliv Rev 61:248-55. 2009
    ..Ongoing clinical studies indicate that CpG ODN are safe and well-tolerated when administered as adjuvants to humans, and that they can support increased vaccine-specific immune responses...
  35. ncbi Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration
    Mathias Heikenwalder
    Institute of Neuropathology, University Hospital of Zurich, Schmelzbergstrasse 12, CH 8091 Zurich, Switzerland
    Nat Med 10:187-92. 2004
    ....
  36. ncbi Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells
    Miren Kerkmann
    Department of Internal Medicine, Division of Clinical Pharmacology, University of Munich, Munich, Germany
    J Immunol 170:4465-74. 2003
    ..Constitutive expression of IRF7 and the ability to produce considerable amounts of IFN-alpha independent of the IFNR seem to represent characteristic features of PDC...
  37. pmc DNA-PKcs, but not TLR9, is required for activation of Akt by CpG-DNA
    Ana Maria Dragoi
    Department of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912, USA
    EMBO J 24:779-89. 2005
    ..Thus, our findings establish a novel role for DNA-PKcs in CpG-DNA signaling and define a CpG-DNA/DNA-PKcs/Akt pathway...
  38. ncbi Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling
    Andrew L Mellor
    Immunotherapy Center, Medical College of Georgia, Augusta, GA 30912, USA
    J Immunol 175:5601-5. 2005
    ....
  39. ncbi TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)
    Risini D Weeratna
    Coley Pharmaceutical Group, Suite 200, Ottawa, ON, Canada K2K 3A2
    Vaccine 23:5263-70. 2005
    ..Using HBsAg as a model antigen in mice, we show CpG ODN to be superior to R-848 for augmenting both humoral and cell mediated immune responses...
  40. pmc A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals
    Ruth D Ellis
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook I, MD 20852, USA
    Vaccine 27:4104-9. 2009
    ..037, 95% CI 1.03, 4.28). In vitro growth inhibition followed the antibody level: median inhibition was 51% (0,1 month interval) versus 85% (0,2 month interval) in antibody from samples taken 2 weeks post-second vaccination (p=0.056)...
  41. pmc Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells
    Anne Sophie Beignon
    Immunologie et Chimie Thérapeutiques, Institut de Biologie Moleculaire et Cellulaire, 15 rue Rene Descartes, F 67084 Strasbourg, France
    Immunology 105:204-12. 2002
    ..Furthermore, with the selection and combination of the appropriate type of adjuvants, immune responses can be modulated towards the desired type of Th phenotype...
  42. pmc The efficiencies of damage recognition and excision correlate with duplex destabilization induced by acetylaminofluorene adducts in human nucleotide excision repair
    Jung Eun Yeo
    Department of Chemistry, Stony Brook University, Stony Brook, NY 11794, USA
    Chem Res Toxicol 25:2462-8. 2012
    ..Our study is the first systematic analysis correlating these three parameters and supports the idea that initial damage recognition by XPC-RAD23B is a key rate-limiting step in NER...
  43. ncbi Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo
    Jong Deok Ahn
    Department of Microbiology, Kyungpook National University, Taegu, Korea
    Circ Res 90:1325-32. 2002
    ..Moreover, the use of stable CDODN specific for AP-1 activity in combination with the highly effective HVJ-liposome method provides a novel potential therapeutic strategy for the prevention of restenosis after angioplasty in humans...
  44. ncbi CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans
    W Nicholas Haining
    Department of Hematology Oncology, Children s Hospital, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 14:5626-34. 2008
    ..CpG-ODN also induce PDC to secrete chemokines that alter lymphocyte migration. Whether CpG-ODN TLR signals enhance antigen-specific immunity and/or trafficking in humans is unknown...
  45. pmc Short- and long-term changes in gene expression mediated by the activation of TLR9
    Sven Klaschik
    Laboratory of Experimental Immunology, Cancer and Inflammation Program, National Cancer Institute, NIH, Frederick, MD 21702, USA
    Mol Immunol 47:1317-24. 2010
    ..The complex bimodal pattern of gene expression elicited by CpG DNA administration provides novel insights into the long-term effects of TLR9 engagement on genes associated with immunity and cell proliferation...
  46. pmc Purified neonatal plasmacytoid dendritic cells overcome intrinsic maturation defect with TLR agonist stimulation
    Marielle C Gold
    Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239, USA
    Pediatr Res 60:34-7. 2006
    ..These results are consistent with the observation that vaccines that effect strong adjuvant activity on dendritic cells can induce protective responses in neonates...
  47. pmc Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation
    Jorg Vollmer
    Coley Pharmaceutical, Langenfeld, Germany
    Immunology 113:212-23. 2004
    ..Our study indicates that TLR9 can mediate either efficient Th1- or Th2-dominated effects depending on whether it is stimulated by CpG or certain non-CpG ODN...
  48. ncbi Mutagenicity of 5-formylcytosine, an oxidation product of 5-methylcytosine, in DNA in mammalian cells
    Hiroyuki Kamiya
    Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita ku, Sapporo 060 0812, Japan
    J Biochem 132:551-5. 2002
    ..The mutation spectrum of 5-fC was broad, and included targeted (5-fC-->G, 5-fC-->A, and 5-fC-->T) and untargeted mutations. These results suggest that the oxidation of 5-mC results in mutations at and around the modified sites...
  49. ncbi The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides
    G J Weiner
    University of Iowa Cancer Center and Department of Internal Medicine, University of Iowa, Iowa City 52242, USA
    J Leukoc Biol 68:455-63. 2000
    ..Clinical evaluation has recently begun to determine whether promising preclinical results with CpG ODN can be translated into effective and tolerable clinical treatment approaches...
  50. ncbi G-quadruplexes induce apoptosis in tumor cells
    Haiyan Qi
    Department of Pharmacology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA
    Cancer Res 66:11808-16. 2006
    ..Interestingly, a number of G-quadruplex ODNs (GQ-ODN) derived from nontelomeric sequences also induced ATM/JNK-dependent apoptosis, suggesting a possible common mechanism of tumor cell killing by GQ-ODNs...
  51. ncbi CpG still rocks! Update on an accidental drug
    Arthur M Krieg
    RaNA Therapeutics, Inc, Cambridge, Massachusetts 02141, USA
    Nucleic Acid Ther 22:77-89. 2012
    ..Along with many positive results have come some failures showing the limitations of several therapeutic approaches. This review summarizes these results to provide an overview of the clinical development of CpG ODN...
  52. ncbi Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA
    Dongbum Kim
    Departments of Microbiology, College of Medicine, Hallym University, Chuncheon, Korea
    BMB Rep 44:758-63. 2011
    ..Therefore, Lipoplex(O) may have a unique potent immunoadjuvant activity which can be useful for various applications involving protein antigens as well as peptides...
  53. ncbi Following G-quartet formation by UV-spectroscopy
    J L Mergny
    Laboratoire de Biophysique, Muséum National d Histoire Naturelle INSERM U201, CNRS URA 481, Paris, France
    FEBS Lett 435:74-8. 1998
    ..This inverted denaturation profile was observed for all G-quartet-forming oligonucleotides studied so far. This technique is very useful in all cases where intramolecular or intermolecular quadruplex formation is suspected...
  54. pmc Competition by inhibitory oligonucleotides prevents binding of CpG to C-terminal TLR9
    Ana M Avalos
    Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Nine Cambridge Center, Cambridge, MA, USA
    Eur J Immunol 41:2820-7. 2011
    ..Ligand binding to C-terminal fragment thus determines the outcome of activation through TLR9...
  55. ncbi Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer
    Vera Hirsh
    McGill University Health Center, Royal Victoria Hospital, Montreal, QC, Canada
    J Clin Oncol 29:2667-74. 2011
    ....
  56. pmc CpG-ODN and MPLA prevent mortality in a murine model of post-hemorrhage-Staphyloccocus aureus pneumonia
    Antoine Roquilly
    Laboratoire UPRES EA 3826 Thérapeutiques cliniques et expérimentales des infections, Faculte de Medecine, Universite de Nantes, Nantes, France
    PLoS ONE 5:e13228. 2010
    ..After hemorrhage, a preventive treatment with CpG-ODN or Monophosphoryl Lipid A increased transcriptional activity in DCs (TNF-α, IFN-β and IL-12p40) and decreased mortality of post-hemorrhage MSSA pneumonia...
  57. pmc Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers
    Sanghoon Kwon
    Department of Microbiology, College of Medicine, Hallym University, Gangwon Do, Republic of Korea
    PLoS ONE 7:e33121. 2012
    ..These results suggest that our improved peptide vaccine technology provides a novel prophylaxis measure as well as therapy for HCC patients with TM4SF5-positive tumors...
  58. ncbi The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes
    R Bomben
    Clinical and Experimental Onco Hematology Unit, Centro di Riferimento Oncologico, I R C C S, Aviano PN, Italy
    Leukemia 26:1584-93. 2012
    ..Overall, targeting of this pathway may represent a novel therapeutic option for management of aggressive CLL...
  59. ncbi Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients
    Daniel E Speiser
    Clinical Tumor Immune Biology Unit, Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland
    J Immunother 33:848-58. 2010
    ..We conclude that vaccination with CpG loaded virus-like nanoparticles is associated with a human CD8 T-cell response with properties of a potential long-term immune protection from the disease...
  60. pmc A naturally occurring variant in human TLR9, P99L, is associated with loss of CpG oligonucleotide responsiveness
    Andriy V Kubarenko
    Department of Toll like Receptors and Cancer, German Cancer Research Centre DKFZ, 69120 Heidelberg, Germany
    J Biol Chem 285:36486-94. 2010
    ..Our data add rs41308230 and rs5743844 to the list of functionally important TLR variants and warrant further research into their relevance for infectious disease susceptibility or responsiveness to CpG-ODN-based therapies...
  61. ncbi An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma
    Collin Jacobs
    Department of Internal Medicine, University Hospitals, University of Munich, Munich, Germany
    Int J Cancer 128:897-907. 2011
    ..Combining ISCOM vaccines with TLR agonists is a promising strategy for breaking tumor immune evasion and deserves further evaluation for the treatment of pancreatic carcinoma...
  62. ncbi Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides
    Tara L Roberts
    Institute for Molecular Bioscience, Cooperative Research Centre for Chronic Inflammatory Diseases, University of Queensland, Brisbane, Australia
    J Immunol 174:605-8. 2005
    ..Thus, TLR9 may be responsible for mediating many published CpG-independent responses to PS-ODN...
  63. ncbi Effects of 8-methylguanine on structure, stability and kinetics of formation of tetramolecular quadruplexes
    Phong Lan Thao Tran
    INSERM U869, European Institute of Chemistry and Biology, Bordeaux University, 2 rue Robert Escarpit, Pessac, France
    Biochimie 93:399-408. 2011
    ....
  64. pmc Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs)
    Hideyuki Yanai
    Department of Immunology, Graduate School of Medicine and Faculty of Medicine, University of Tokyo, Tokyo 113 0033, Japan
    Proc Natl Acad Sci U S A 108:11542-7. 2011
    ..We discuss our findings in relation to the critical role of HMGBs in initiating immune responses and the possible use of these ni-ODNs in therapeutic interventions...
  65. pmc Effect of suppressive oligodeoxynucleotides on the development of inflammation-induced papillomas
    Hidekazu Ikeuchi
    Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA
    Cancer Prev Res (Phila) 4:752-7. 2011
    ..Of greatest import, Sup ODN reduce papilloma formation in a dose- and sequence-dependent manner. These findings suggest that Sup ODN may provide a novel means of preventing inflammation and associated oncogenesis...
  66. ncbi Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes
    Erdem Erikçi
    Bilkent University, Department of Molecular Biology and Genetics, Biotherapeutic ODN Lab, Bilkent, 06800 Ankara, Turkey
    Biomaterials 32:1715-23. 2011
    ....
  67. ncbi TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects
    Michele Sommariva
    Department of Human Morphology and Biomedical Sciences Citta Studi, Universita degli Studi di Milano, Italy
    Cancer Res 71:6382-90. 2011
    ..Taken together, the findings provide evidence that the tumor microenvironment can sensitize cancer cells to DNA-damaging chemotherapy, thereby expanding the benefits of CpG-ODN therapy beyond induction of a strong immune response...
  68. pmc Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates
    Montserrat Puig
    Laboratory of Immunology, Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Nucleic Acids Res 34:6488-95. 2006
    ..This technology fosters the development of more efficient immunotherapeutic oligonucleotide formulations for the treatment of allergies, cancer and infectious diseases...
  69. pmc Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy
    Brandon Kwong
    Department of Biological Engineering, Massachusetts Institute of Technology, 77 Mass Ave, Cambridge, MA 02139, USA
    Biomaterials 32:5134-47. 2011
    ..The development of a delivery strategy capable of inducing robust anti-tumor responses concurrent with minimal systemic side effects is crucial for the continued progress of potent immunotherapies toward widespread clinical translation...
  70. ncbi Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself
    Jiali Li
    Department of Medicine, Division of Oncology, Stanford University Medical Center, Stanford, CA 94305, USA
    J Immunol 179:2493-500. 2007
    ..These results indicate that activation of Ag presentation by cells within the tumor via TLR9 stimulation can be an effective form of immunotherapy. This study forms the basis of an ongoing clinical trial in patients with lymphoma...
  71. ncbi Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice
    Suzanne M Bal
    Division of Drug Delivery Technology, Leiden Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands
    Eur J Pharm Sci 45:475-81. 2012
    ..However, the strength and quality of the response depends on the immunopotentiator as well as the route of administration...
  72. ncbi Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN
    B Jahrsdorfer
    Division of Clinical Pharmacology, Department of Internal Medicine, University of Munich, Ziemssenstrasse 1, 80336 Munich, Germany
    J Leukoc Biol 72:83-92. 2002
    ..Immunostimulatory CpG ODN may have a therapeutic potential in patients with B-CLL, especially those with low s-TK activity...
  73. pmc DEC-205 is a cell surface receptor for CpG oligonucleotides
    Mireille H Lahoud
    Centre for Immunology, Burnet Institute, Melbourne, VIC 3004, Australia
    Proc Natl Acad Sci U S A 109:16270-5. 2012
    ..Our findings identify an important receptor for class B CpG ODN and reveal a unique function for DEC-205...
  74. pmc G4 resolvase 1 tightly binds and unwinds unimolecular G4-DNA
    Banabihari Giri
    Department of Cancer Biology and the Comprehensive Cancer Center of Wake Forest University School of Medicine, Winston Salem, USA
    Nucleic Acids Res 39:7161-78. 2011
    ..This report provides evidence that G4R1/RHAU tightly binds and unwinds unimolecular G4-DNA structures...
  75. pmc CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells
    David F LaRosa
    Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Immunol Lett 108:183-8. 2007
    ..Here we show that this costimulatory effect is sufficient to abrogate suppression by Tregs. These data indicate a previously undefined role for TLR ligands in directly modulating CD4+ T cell responses...
  76. pmc CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD4+ T cells through a TLR9- and MyD88-independent mechanism
    Angela Landrigan
    Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    J Immunol 187:3033-43. 2011
    ..Our studies reveal a striking and unexpected ability of ODNs to directly activate and polarize T cells, presenting an opportunity to enhance the paradigm for selection of therapeutic ODNs in humans...
  77. pmc 'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents
    Dong Yu
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Nucleic Acids Res 30:4460-9. 2002
    b>Oligodeoxyribonucleotides containing CpG dinucleotides (CpG DNAs) are currently being evaluated as novel immunomodulators in clinical trials...
  78. ncbi Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis
    Peter S Creticos
    Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, USA
    N Engl J Med 355:1445-55. 2006
    ..Conjugating immunostimulatory sequences of DNA to specific allergens offers a new approach to allergen immunotherapy that reduces acute allergic responses...
  79. pmc An efficient recombination system for chromosome engineering in Escherichia coli
    D Yu
    Gene Regulation and Chromosome Biology Laboratory and Mouse Cancer Genetics Program, National Cancer Institute, Division of Basic Science, National Cancer Institute Frederick Cancer Research and Development Center, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 97:5978-83. 2000
    ..This system will be especially useful for the engineering of large bacterial plasmids such as those from bacterial artificial chromosome libraries...
  80. ncbi G-quadruplex DNA assemblies: loop length, cation identity, and multimer formation
    Nicolas Smargiasso
    Mass Spectrometry Laboratory, GIGA Research, University of Liege, Belgium
    J Am Chem Soc 130:10208-16. 2008
    ..The nature of the cation also has an influence on the adopted structures, with K(+) inducing more parallel multimers than NH4(+) and Na(+). Structural possibilities are discussed for the new quadruplex higher-order assemblies...
  81. ncbi Structural basis for the recognition of the FapydG lesion (2,6-diamino-4-hydroxy-5-formamidopyrimidine) by formamidopyrimidine-DNA glycosylase
    Franck Coste
    Centre de Biophysique Moleculaire, UPR4301, CNRS, rue Charles Sadron, 45071 Orleans Cedex 02, France
    J Biol Chem 279:44074-83. 2004
    ..The significant differences between the Fpg recognition modes of 8-oxodG and FapydG provide new insights into the Fpg substrate specificity...
  82. pmc Tetramolecular G-quadruplex formation pathways studied by electrospray mass spectrometry
    Frederic Rosu
    Department of Chemistry B6c, University of Liege, Liege, Belgium
    Nucleic Acids Res 38:5217-25. 2010
    ..We also show that the addition of methanol to the monomer solution significantly accelerates the cation-induced G-quadruplex assembly...
  83. ncbi Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus
    Rahul D Pawar
    Medizinische Poliklinik, University of Munich, Pettenkoferstrasse 8a, 80336 Munich, Germany
    J Am Soc Nephrol 18:1721-31. 2007
    ..Hence, TLR-7 is proposed as a novel and potential therapeutic target in systemic lupus erythematosus...
  84. ncbi HIV-1 nucleocapsid protein as a nucleic acid chaperone: spectroscopic study of its helix-destabilizing properties, structural binding specificity, and annealing activity
    Maria A Urbaneja
    AIDS Vaccine Program, SAIC Frederick, Building 535 424, National Cancer Institute Frederick, Frederick, MD 21702 1201, USA
    J Mol Biol 318:749-64. 2002
    ....
  85. pmc Type-A CpG oligonucleotides activate exclusively porcine natural interferon-producing cells to secrete interferon-alpha, tumour necrosis factor-alpha and interleukin-12
    Laurence Guzylack-Piriou
    Institute of Virology and Immunoprophylaxis, Mittelhausern, Switzerland
    Immunology 112:28-37. 2004
    ..These results represent an important basis for the application of CpG-ODN as adjuvants for the formulation of novel vaccines and demonstrate the importance of the pig as an alternative animal model for this approach...
  86. pmc TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis
    Stacey L Demento
    Department of Biomedical Engineering, Yale University, New Haven, CT 06511, USA
    J Immunol 185:2989-97. 2010
    ..Ultimately, compared with alum, this system offered superior protection in a mouse model of WN virus encephalitis...
  87. pmc Mechanism of regulation of bcl-2 mRNA by nucleolin and A+U-rich element-binding factor 1 (AUF1)
    Daniella Ishimaru
    Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    J Biol Chem 285:27182-91. 2010
    ..Based on our findings, we propose a model that illustrates the opposing roles of nucleolin and AUF1 in regulating bcl-2 mRNA stability...
  88. ncbi Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN
    N Kadowaki
    Department of Immunobiology, DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, CA 94304, USA
    J Immunol 166:2291-5. 2001
    ....
  89. ncbi Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses
    Dominique B Hoelzinger
    Department of Immunology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    J Immunol 184:6833-42. 2010
    ..These studies demonstrate that neutralization of CCL1 can be used as an adjuvant to antitumor immunotherapy, as a means of reversing the immunosuppressive function of Tregs without compromising T cell effector function...
  90. pmc A single-cell pedigree analysis of alternative stochastic lymphocyte fates
    E D Hawkins
    Immunology Division, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Victoria 3050, Australia
    Proc Natl Acad Sci U S A 106:13457-62. 2009
    ..Together, these results highlight the internal cellular mechanisms that control immune responses and provide a foundation for the development of new mathematical models that are correct at both single-cell and population levels...
  91. ncbi Cellular responses to targeted genomic sequence modification using single-stranded oligonucleotides and zinc-finger nucleases
    Petter Angell Olsen
    Section for Cellular and Genetic Therapy, Institute of Microbiology, Rikshospitalet University Hospital HF, Oslo, Norway
    DNA Repair (Amst) 8:298-308. 2009
    ..On the contrary, cells corrected using ZFNs displayed normal cell cycle distribution and lower rates of DNA damage...
  92. ncbi Use of CpG oligodeoxynucleotides as immune adjuvants
    Dennis M Klinman
    Section of Retroviral Immunology, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Immunol Rev 199:201-16. 2004
    ..Ongoing clinical studies indicate that CpG ODNs are safe and well tolerated when administered as adjuvants to humans, and in some cases, they increase vaccine-induced immune responses...
  93. ncbi CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants
    G B Lipford
    Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Germany
    Eur J Immunol 27:2340-4. 1997
    ..Thus ssDNA oligomers may serve as inexpensive and safe vaccine adjuvants and, in addition, differential effects due to sequence may allow for directed responses...
  94. ncbi CpG oligodeoxynucleotide enhances tumor response to radiation
    Luka Milas
    Department of Experimental Radiation Oncology 66, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4095, USA
    Cancer Res 64:5074-7. 2004
    ..These results show that CpG ODNs are potent enhancers of tumor radioresponse and as such have potential to improve clinical radiotherapy...
  95. pmc Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice
    Ming Hsi Huang
    Vaccine Research and Development Center, National Health Research Institutes, Zhunan Town, Taiwan
    PLoS ONE 5:e12279. 2010
    ..We assessed the immunogenicity of an inactivated H5N1 whole-virion vaccine (A/Vietnam/1194/2004 NIBRG-14, clade 1) formulated with emulsified nanoparticles and investigated whether it can induce cross-clade protecting immunity...
  96. pmc Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells
    Xueqing Liang
    Department of Pediatrics, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Blood 115:5041-52. 2010
    ..These findings provide new understanding of CpG ODN-mediated antitumor effects and support for the development of TLR9-targeted therapy for human CLL...
  97. pmc Interleukin 6: insights to its function in skin by overexpression in transgenic mice
    K Turksen
    Howard Hughes Medical Institute, Department of Molecular Genetics and Cell Biology, University of Chicago, IL 60637
    Proc Natl Acad Sci U S A 89:5068-72. 1992
    ..If IL-6 plays additional roles in the skin, it is likely to act synergistically with factors that IL-6 alone cannot induce...
  98. ncbi Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma- and IL-12-mediated signaling
    Hidekazu Shirota
    Section of Retroviral Immunology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD 20892, USA
    J Immunol 173:5002-7. 2004
    ..These changes indirectly support the generation of Th2-dominated immune responses. Suppressive ODN may thus represent a novel approach to influence the Th1:Th2 balance in vivo...
  99. ncbi Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns
    Dominique De Wit
    Hôpital Erasme Department of Immunology, 808, Route de Lennik, B 1070 Brussels, Belgium
    Blood 103:1030-2. 2004
    ..These findings might be relevant to the increased susceptibility of human newborns to infections as well as to the use of CpG oligodeoxynucleotides as vaccine adjuvants in the neonatal period...
  100. ncbi A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties
    Ulrike Samulowitz
    Coley Pharmaceutical GmbH A Pfizer Company, Dusseldorf, Germany
    Oligonucleotides 20:93-101. 2010
    ..Taken together, we have discovered a novel class of CpG ODNs, the P-Class, with promising superior activity for disease application...
  101. pmc Site-specific incorporation of N-(deoxyguanosin-8-yl)-2-acetylaminofluorene (dG-AAF) into oligonucleotides using modified 'ultra-mild' DNA synthesis
    Ludovic C J Gillet
    Institute for Molecular Cancer Research, University of Zürich August Forel Strasse 7, 8008 Zurich, Switzerland
    Nucleic Acids Res 33:1961-9. 2005
    ..Our synthetic approach should facilitate comprehensive studies of the mechanisms of repair and mutagenesis induced by dG-AAF adducts in DNA and should be of general use for the incorporation of base-labile functionalities into DNA...

Research Grants62

  1. Targeted Lipopolyplexes for Oligonucleotide Delivery to AML
    Robert J Lee; Fiscal Year: 2012
    ..to develop novel nanotechnology to create multifunctional immunonanoparticles for the delivery antisense oligodeoxyribonucleotides to treat acute myeloid leukemia (AML)...
  2. Chemistry and Biology of DNA Carboxyalkylation
    Yinsheng Wang; Fiscal Year: 2013
    ..Aim 3, to synthesize oligodeoxyribonucleotides harboring a carboxyalkylated lesion at a specific site...
  3. Cellular and Molecular Effectors of Synovitis
    Paul J Anderson; Fiscal Year: 2010
    ..Project 1 will determine how interactions between CpG-containing oligodeoxyribonucleotides and TLR9 in macrophage/dendritic cells trigger an immune cascade that induces the expression of IFN-..
  4. ROS-induced Nucleic Acid Damage
    Yinsheng Wang; Fiscal Year: 2010
    ..In addition, we are going to construct oligodeoxyribonucleotides harboring site-specifically incorporated oxidative DNA lesions and use them as substrates for in-vitro ..
  5. SOMATOSTATIN RECEPTORS--CLASSIFICATION OF NEUROBLASTOMAS
    M O DORISIO; Fiscal Year: 1999
    ..Down-regulation of SSR1, SSR2, and SSR3 will be attempted using antisense oligodeoxyribonucleotides. Functional experiments will examine the effect of somatostatin and stable analogs of somatostatin on ..
  6. (2'-5')AN DEPENDENT ENDONUCLEASE AND INTERFERON ACTION
    GEORGIA SMITH; Fiscal Year: 1992
    ..The partial amino acid sequence will be used as a basis for the synthesis of oligodeoxyribonucleotides encoding RNase L...
  7. Exercise, Antioxidants, and I-R Injury
    Scott Powers; Fiscal Year: 2006
    ..Using both pharmacological and molecular approaches (e.g. antisense oligodeoxyribonucleotides to MnSOD), we will independently prevent the exercise-induced synthesis of myocardial MnSOD and GSH...
  8. ONTOGENY AND EXPRESSION OF THE CFTR IN BRAIN
    ANDREW MULBERG; Fiscal Year: 2003
    ..Antisense oligodeoxyribonucleotides developed against the CFTR gene and inhibitors of CFTR C1 conductance will be screened for effects upon ..
  9. REGULATION OF 06-METHYLGUANINE DNA METHYLTRANSFERASE
    Edward Bresnick; Fiscal Year: 1991
    ..at various guanines within and in the region of codon 12 by using synthetic 15 mer double-stranded oligodeoxyribonucleotides; and e) characterize the DNA repair capabilities of Cosmid 102-transformed excision repair-deficient CHO ..
  10. DNA SYNTHESIS AND HYDROLYSIS
    RICHARD BRODY; Fiscal Year: 1990
    ..coli with specifically modified oligodeoxyribonucleotides. A characterization of this simplified system will be an important step towards being able to understand ..
  11. N2 ALKYIG ADDUCTS--MUTATIONS AND POLYMERASE INTERACTIONS
    Steven Akman; Fiscal Year: 2004
    ..This proposal will close that gap in our understanding of DNA alkylator-induced mutagenesis by: 1) Oligodeoxyribonucleotides containing single N2-ethylguanine, N2-isopropylguanine, O6-ethyl guanine, and O6-isopropylguanine bases ..
  12. GENE ENGINEERING OF DENDRITIC CELLS AND TRANSPLANTATION
    Angus Thomson; Fiscal Year: 2006
    ..r) adenovirus (Ad)-induced, NFkappaB-dependent dendritic cell (DC) maturation by NFkappaB decoy oligodeoxyribonucleotides (ODN) permits functional expression of a potent immunosuppressive transgene product (CTLA4Ig)...
  13. Visualizing the Movement of mRNAs in Living Cells
    Sanjay Tyagi; Fiscal Year: 2007
    ..of action of natural SNARE-mediated vesicle fusion, this method employs complementary single-stranded oligodeoxyribonucleotides that are anchored to the surfaces of cells and vesicles to facilitate their fusion...
  14. ANTI-HIV AIDS AGENTS TARGETED TO THE RNA TEMPLATE
    STEPHEN BYRN; Fiscal Year: 1990
    ..The oligodeoxyribonucleotides are designed to target important sequences of the HTLV-III/LAV/HIV gene...
  15. DERIVATIZATION OF DNA AT THE 1' POSITION OF RIBOSE
    STEPHEN WOSKI; Fiscal Year: 1999
    ..When incorporated in oligodeoxyribonucleotides in the place of natural nucleosides, these residues will produce functionalized DNA s where the ..
  16. Therapeutic use of inhibitory DNA sequences in animal models of lupus
    Petar Lenert; Fiscal Year: 2006
    ..Future extension of these studies to humans may lead to the design of novel therapeutic agents for human SLE. [unreadable] [unreadable] [unreadable]..
  17. Mechanism of Action of Inhibitory CpG Oligonucleotides
    Petar Lenert; Fiscal Year: 2009
    ..Short synthetic oligodeoxyribonucleotides (ODN) have facilitated studies of structure-function relationships...
  18. Early Life Exposure to Microbial Products and Asthma
    Joel Kline; Fiscal Year: 2005
    ..Question 2A: What mediators promote immune tolerance induced by early life exposure to microbial products? Question 2B: What cells are responsible for immune tolerance induced by early life exposure to microbial products? ..
  19. REVERSE TRANSCRIPTASES IN THE PROKARYOTES
    Masayori Inouye; Fiscal Year: 1999
    ..Exploration of possible functions of retrons in E. coli cells; 3. Studies of retrons as mobile elements; 4. In vivo synthesis of oligodeoxyribonucleotides using retrons as a vector.
  20. Helminth-Induced Immune Tolerance in Asthma
    Joel Kline; Fiscal Year: 2005
    ..Although completion of the second Aim is almost certainly beyond the scope of this two-year developmental research grant, these studies will be continued and extended through an R01 grant application. ..
  21. Induction of Respiratory Tolerance By Mucosal CpG ODN
    Joel Kline; Fiscal Year: 2006
    ..Aim 2: To evaluate whether anti-inflammatory effects of airway mucosal exposure to CpG-ODN are mediated through regulatory T-lymphocytes. ..
  22. A Novel Inhibitor of Stat3 for Prostate Cancer Therapy
    Naijie Jing; Fiscal Year: 2009
    ..abstract_text> ..
  23. ROS-induced Nucleic Acid Damage
    Yinsheng Wang; Fiscal Year: 2006
    ..The outcome of the research proposed here will provide better understanding of the biological consequences of oxidative damage on nucleic acids by ROS and their implications in human health. ..
  24. Post-translational Modifications of High-mobility Group Proteins
    Yinsheng Wang; Fiscal Year: 2009
    ..In addition, the outcome of proposed studies may provide important molecular biomarkers for cancer diagnosis and prognosis. ..
  25. DEVELOPING A POTENT INHIBITOR OF HIV-I INTEGRASE
    Naijie Jing; Fiscal Year: 2001
    ....
  26. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre L Triozzi; Fiscal Year: 2010
    ....
  27. Uveal Melanoma Micrometastasis
    Pierre L Triozzi; Fiscal Year: 2010
    ..Micrometastases, microscopic deposits of tumor that have spread via the bloodstream, are present in many patients with uveal melanoma at diagnosis. This project will test new methods of identifying and inhibiting these deposits. ..
  28. THE TRUE NATURE OF OXIDATIVE DNA DAMAGE
    HAROLD BOX; Fiscal Year: 2003
    ..Two cell lines will be examined for the lesions deemed most representative of the nature of oxidative DNA damage. Three different methods for subjecting cells to oxidative stress will be utilized. ..
  29. CpG ODN as an Immune Adjuvant
    George Weiner; Fiscal Year: 2006
    ..The results of these studies will allow for the rational design of the next generation of moAb-based approaches to the therapy of B-cell and other malignancies. ..
  30. Monoclonal Antibody Therapy for Follicular Lymphoma
    Jonathan Friedberg; Fiscal Year: 2007
    ..abstract_text> ..
  31. LC-MS/MS Assessments of Apoptosis/DNA Damage/Repair
    HAROLD BOX; Fiscal Year: 2005
    ..Differences in cell function revealed by LC-MS/MS assay will be complemented by array studies of gene expression. The first clinical application will be ovarian cancer tissue. ..
  32. RADIATION DAMAGE IN DNA
    HAROLD BOX; Fiscal Year: 2004
    ..It would attempt to evaluate the capacity of cells to repair base damage using cell extract and DNA substrate, again relying on ion trap technology. ..
  33. Assays for ROS-induced DNA damage
    HAROLD BOX; Fiscal Year: 2003
    ..These products will be offered commercially for facilitating DNA damage and repair by 32P-postlabeling or by LC-MS. ..
  34. Controlling DNA Condensation In Vitro
    Nicholas Hud; Fiscal Year: 2005
    ..Dr. Hud's results will have direct implications on the feasibility of using static DNA structures in the development of nonviral gene delivery systems. ..
  35. 2nd International Conference on Prostate Cancer Research
    David Lubaroff; Fiscal Year: 2002
    ..Selection of the travel awardees will be made by a subcommittee of the Organizing Committee and will be based upon the quality of the research contained in the submitted abstracts. ..
  36. INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARD (T32)
    George Weiner; Fiscal Year: 2004
    ..On completion of the program, it is expected that trainees will have a thorough understanding of the various aspects of cancer research, and be able to function as independent cancer researchers in an academic setting. ..
  37. LEUKEMIA THERAPY WITH MIHA SPECIFIC T CELLS
    Wei Chen; Fiscal Year: 2002
    ..3. To develop methods develops for in vitro induction of MiHA-specific T cells for leukemia therapy. ..
  38. Mechanisms of Nucleic Acid Uptake and The Role of cMDH
    Basil Hanss; Fiscal Year: 2008
    ..2) To determine the functional role of cytosolic malatedehydrogenase in nucleic acid transport; 3) To establish the topology of cMDH relative to plasma membrane. ..
  39. MECHANISMS OF IL-2 IMMUNE ENHANCEMENT IN HUMANS
    Charlotte Cunningham Rundles; Fiscal Year: 2001
    ..Thus, this application will focus on the cellular and molecular mechanisms by which IL-2 reconstitutes T cell immunity in this model system. ..
  40. Primary Immune Deficiency Consortium Conference
    Charlotte Cunningham Rundles; Fiscal Year: 2008
    ..Principle topics will focus on: Diagnosis of Immunodeficiency; Genetics, Immune Reconstruction, and the Use of Standard and Novel Therapies. ..
  41. An extract of pinecones as a potent DNA vaccine adjuvant
    William Bradley; Fiscal Year: 2003
    ..The levels of antigen-specific antibodies and CTL will be examined. Overall, this study will determine if PCE can be safely and effectively used as a DNA vaccine adjuvant ..
  42. MOLECULAR DYNAMICS SIMULATIONS OF DNA OLIGONUCLEOTIDES
    David Beveridge; Fiscal Year: 2003
    ..abstract_text> ..
  43. Prefrontal cortex and memory storage
    Pramod K Dash; Fiscal Year: 2010
    ....
  44. DNA DAMAGE IN MOUSE TUMORS EVAL BY IR SPECTROSCOPY
    DONALD MALINS; Fiscal Year: 2002
    ..Third, we shall evaluate how two chemotherapeutic drugs with different modes of action affect detectable DNA lesions, using the FT-IR technology, and attempt to correlate this with their activity in tumor formation. ..
  45. Tumor-Targeting Oligonucleotides
    Paula J Bates; Fiscal Year: 2010
    ..The third aim is to incorporate the optimal tumor-targeting sequences into antisense, siRNA and immunomodulatory oligonucleotides in order to determine if this leads to superior uptake and activity. ..
  46. Novel Model to Predict Safety and Efficacy of Microbicides
    Gregory Prince; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  47. Ethanol-fed, CpG-treated mice: Listeria susceptibility
    Nancy Ray; Fiscal Year: 2005
    ..These studies could lead to treatments for protecting alcoholic patients from intracellular bacterial infections such as those caused by L. monocytogenes or Mycobacterium tuberculosis (TB). ..
  48. Recognition of Multiply Damaged Sites in DNA
    Carlos de Los Santos; Fiscal Year: 2005
    ..Additionally, it would afford additional time to the applicant for the establishment of an independent research program in his laboratory. ..
  49. Effects of Formamidopyrimidine Lesions on DNA
    Marc Greenberg; Fiscal Year: 2006
    ..abstract_text> ..
  50. Nucleic Acid Gordon Research Conference
    ANNA PYLE; Fiscal Year: 2004
    ..Poster sessions and optional recreational activities will stimulate informal interactions among participants. ..
  51. Ambient TLR Ligand Exposures and the Genesis of Asthma
    Anthony Horner; Fiscal Year: 2008
    ..abstract_text> ..
  52. Structure and Function of Clustered DNA Lesions
    Carlos de Los Santos; Fiscal Year: 2007
    ..abstract_text> ..
  53. Vertical Coverage Arrays in analyzing transcription
    John Welsh; Fiscal Year: 2004
    ..This data will be used to construct a class predictor that predicts whether or not a particular transcription factor is likely to be involved in the regulation of a gene. ..
  54. Evolving Novel Polymerases for Genome Sequencing
    FLOYD ROMESBERG; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  55. MOLECULAR PATHOLOGY OF LPS-INDUCED INJURY
    Richard Ulevitch; Fiscal Year: 2004
    ..The results of these studies, if successfully accomplished, may lead to the development of new strategies to control the innate immune responses in bacterial infection. ..
  56. MICROBES, DENDRITIC CELL SUBSETS AND T-CELL IMMUNITY
    Bali Pulendran; Fiscal Year: 2008
    ..abstract_text> ..
  57. Theoretical and MD Simulation Studies of U1A-RNA Binding and Specificity
    David Beveridge; Fiscal Year: 2006
    ....
  58. DNA Damage as Women Age: Implications for Breast Cancer
    DONALD MALINS; Fiscal Year: 2005
    ....
  59. Epithelial Na channel (ENaC) polymorphisms in hyptertention
    James Stockand; Fiscal Year: 2007
    ..Preliminary results support the feasibility of this investigation and suggest that this line of inquiry will yield significant and novel findings. [unreadable] [unreadable]..
  60. Ler control of EPEC virulence
    JAY MELLIES; Fiscal Year: 2008
    ..Further elucidation of the molecular mechanisms of Ler action should lead to the development of chemotherapeutic agents directed against EPEC and related E. coli O157 bacteria. [unreadable] [unreadable] [unreadable] [unreadable]..
  61. FLOW CYTOMETRY INSTRUMENT
    ZUHAIR BALLAS; Fiscal Year: 2001
    ..abstract_text> ..
  62. A Role for Nucleolin in Malignant Transformation?
    Paula Bates; Fiscal Year: 2005
    ..abstract_text> ..